Figure 2From: Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection Proportion of simeprevir/PR-treated patients achieving SVR24 in the PILLAR and ASPIRE studies. Back to article page